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Abstract
Background: Increasing numbers of children and adolescents with type 1 diabetes (T1D) have been placed on insulin pump
therapy. Nevertheless, data are limited regarding patterns of pump use during the first year of treatment and the clinical and
socioeconomic factors associated with early use of pump therapy. Therefore, we sought to determine factors associated with
pump therapy within the first year of diagnosis in youth enrolled in the Pediatric Diabetes Consortium (PDC) T1D New-
Onset (NeOn) Study.
Subjects and Methods: The NeOn Study includes youth <19 years old at T1D diagnosis who have been followed from the
time of diagnosis at seven U.S. pediatric diabetes centers. Cox regression was used to determine factors associated with
transition from injection to pump therapy during the first year of T1D in 1,012 participants.
Results: Twenty-seven percent (n = 254) of participants began pump therapy within the first year of diagnosis, ranging from
18% to 59% among the seven centers. After adjusting for center effect, factors associated with pump use in multivariate
analysis included private health insurance (37% vs. 7%; P < 0.001), having annual household income over $100,000 (50% vs.
15%; P < 0.001), and non-Hispanic white race (36% vs. 11%; P < 0.001). The hemoglobin A1c level did not appear to influence
the decision to initiate pump use.
Conclusions: Participants of non-Hispanic white race and higher socioeconomic status were more likely to be placed on
pumps during the first year. Further investigations are needed to gain a better understanding of barriers to use of pumps in
youth with T1D, especially in disadvantaged and minority families.
Introduction
Continuous subcutaneous insulin infusion via an in-sulin pump has become a widely used tool for insulin
delivery for adult and pediatric patients with type 1 diabetes
(T1D). The pump allows for delivery of insulin that mimics
physiological insulin release1,2 and facilitates increased flexi-
bility inmanaging changes in diet and exercise,3 which in turn
contributes to improved quality of life.4 Furthermore, the
pump can help patients achieve and maintain good glycemic
control without increased risks of severe hypoglycemia or
diabetic ketoacidosis (DKA).3,5 Past research has suggested
that, among patients with T1D started on insulin pump
therapy, those diagnosed up to 1 year before had lower mean
hemoglobin A1c (HbA1c) levels during the entire follow-up
period, compared with those who had the disease for longer
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time.6 Shorter diabetes duration at the time of pump initiation
has been shown to be associated with an increased likelihood
of achievement of target HbA1c.
7 Furthermore, initiation of
insulin pump therapy at diagnosis has been shown to im-
prove glycemic control.8
Over the past 10 years, increasing numbers of children and
adolescents with T1D have been placed on insulin pump
therapy, and large numbers of clinical outcome studies have
confirmed the benefits of pump therapy in the pediatric age
group.3–5,9,10 Nevertheless, data are limited regarding real-
world patterns of pump use during the first year of treatment
of T1D in children and adolescents and the clinical and so-
cioeconomic factors that are associated with early use of
pump therapy. Consequently, the major focus of this inves-
tigation was to determine factors associated with insulin
pump use within the first year of T1D diagnosis in youth
enrolled in the Pediatric Diabetes Consortium (PDC) T1D
New-Onset (NeOn) Study. Portions of this work have been
presented elsewhere in abstract form.11–13
Subjects and Methods
The PDCNeOn Study enrolled 1,052 participants between
July 2009 and April 2011. The protocol was approved by the
Institutional Review Board at each of the seven participating
centers. Informed consent was obtained from participants 18
years of age or older and from the parents/guardians of
those less than 18 years of age. Assent was obtained from
participants under 18 years of age as required by local In-
stitutional Review Board regulations. To be eligible for en-
rollment in the study, patients had to be less than 19 years of
age and managed at one of the seven PDC centers within
3months of diagnosis. A detailed description of the PDC and
of the design of the study has been published previously.14
The analyses reported herein included data from 1012 par-
ticipants; 36 were excluded because of participation in an
intervention study, and four were excluded for not having a
follow-up visit.
Data collection
Demographic, socioeconomic, and clinical characteristics
datawere collected frommedical records and from interviews
with the participant and/or parent. Follow-up visits were
completed during regularly scheduled office visits, and all
visits during the first year post-diagnosis were entered in the
study database using standardized electronic case report
forms.
Statistical analysis
The outcome for analysis was insulin pump use within 365
days of diagnosis. The cumulative incidences of pump use
were calculated using the Kaplan–Meier estimator. Data of
participants not using a pumpwere censored at their last visit
or Day 365, whichever came earlier. Cox regression was used
to determine the association of the following baseline factors
with pump use in the first year: age, gender, race/ethnicity,
health insurance status, parental education, family income,
family structure, and DKA at diagnosis. Family income and
parent educationwere analyzed as ordinal variables. Agewas
analyzed as categorical because of the detection of significant
nonlinear effects. Initial bivariate models were constructed for
each baseline factor one at a time adjusting for clinical center.
A baseline multivariate model was then constructed using
stepwise selection with values of P < 0.10 required to be in-
cluded in the model. A separate model was also constructed
withHbA1c added as a time-dependent predictor of pumpuse
so that any effect of insulin pump use on subsequent HbA1c
values would not confound this analysis. Because of multiple
comparisons, only factors with values of P < 0.01 were con-
sidered statistically significant, although factors with values
of P < 0.10 were included in the model to adjust for potential
confounding.
Additional models were run to test for interactions among
the factors identified in the analyses above. The only inter-
action identified was age by clinical center (P < 0.01). Further
inspection revealed that both the age effect and its interaction
with center were primarily driven by a single center (labeled
Center F in Results) that had six of eight cases in the youngest
age group (< 2 years) switch to a pump. In sensitivity analyses
excluding these eight cases, the age effect and its interaction
with center were no longer significant (P = 0.26 and 0.27, re-
spectively). Results were similar in an additional sensitivity
analysis excluding all cases from Center F. A similar issue
Table 1. Participant Demographics, Socioeconomic
Status, and Clinical Factors at Diagnosis (n = 1,012)
Factor n %
All 1012 100%
Age at diagnosis (years)
< 2 46 5%
2–< 5 149 15%
5–< 12 554 55%
12–< 19 263 26%
Mean (SD) 9.1 (4.2)
Range 0.7–18.8
Gender
Female 507 50%
Race/ethnicity
Non-Hispanic white 638 64%
Hispanic or Latino 212 21%
Black/African American 82 8%
Other/more than one race 60 6%
Health insurance
Private 652 66%
CHIP/Medicaid/Medicare 297 30%
Military 19 2%
None 22 2%
Parent education
High school or less 287 35%
AA 118 14%
BS/BA 238 29%
MS/MA or professional degree 185 22%
Family income
< $25,000 99 15%
$25,000–$49,999 130 19%
$50,000–$74,999 111 16%
$75,999–$99,999 95 14%
‡ $100,000 239 35%
Family structure
Lives with both parents 701 69%
Number of participants with missing data: race/ethnicity (n = 20),
health insurance (n = 22), parent education (n= 184), family income
(n = 338), family structure (n = 2).
CHIP, Children’s Health Insurance Program.
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occurred with a violation of the proportional hazards as-
sumption detected in the youngest age group. This also was
primarily driven by the eight cases mentioned above and was
no longer present in sensitivity analysis when they were ex-
cluded. Results are presented including all subjects (primary
analysis) as well as by age for Center F versus other centers to
illustrate the interaction.
Missing covariates were treated as a separate category for
discrete variables, and amissing value indicator was added to
themodel for continuous variables. Results were similar using
Rubin’s multiple imputation (data not shown). All reported P
values are two-sided. All analyses were conducted using SAS
version 9.3 software (SAS Institute, Cary, NC).
Results
The mean age at diagnosis of the 1012 participants was
9.1 – 4.2 years (range, 0.7–18.8 years). Fifty percent were
female, 64% were non-Hispanic white, 66% had private
health insurance, and 69% lived in two-parent households
(Table 1).
Overall, 254 participants (Kaplan–Meier incidence of 27%)
used an insulin pump during the first year of T1D, and 16
additional participants were prescribed an insulin pump but
had not used it by 1 year (treated as not using an insulin pump
for analysis). Themedian duration of T1D at the time of pump
initiation was 7.0 months (25th–75th percentiles, 4.4–9.4
months). Relatively few participants used a pump during the
first month of T1D; thereafter, the percentage of participants
using a pump increased linearly during the rest of the first
year (Fig. 1). Mean age at the time of pump initiation was 9.2
years (range, 1.0–18.4 years).
The incidence of pump use among participants during the
first year varied among the seven PDC clinical centers, rang-
ing from 18% to 59% (P < 0.001). Bivariate analysis (with ad-
justment for clinical center) using Cox regression showed that
factors associated with a higher incidence of pump use in-
cluded private health insurance (37% vs. 7%; P < 0.001), living
with both parents (33% vs. 13%; P < 0.001), non-Hispanic
white race (36% vs. 11%; P < 0.001), annual family income over
$100,000 (50% vs. 15%; P< 0.001), and a parent with a college
education (33% vs. 15%; P< 0.001). Results were similar in
multivariate analysis except that the effect of family struc-
ture and parent education were confounded with the other
socioeconomic factors so that a possible independent effect
could not be confirmed or ruled out. Therewas an effect of age
at one clinical center (Center F in Fig. 2) (P < 0.001) that was
not observed at the other six centers (P = 0.17). The mean
HbA1c level for pump users at the time of initiation (– 30 days;
n= 187) was 7.3 – 1.1% (range, 5.0–14.0%) and similar to that
of those who did not use a pump (Cox regression model
P = 0.26).
Discussion
The trend for more frequent use of insulin pump therapy
earlier in the course of pediatric T1D at U.S. treatment centers
was reflected in our finding that insulin pump therapy was
initiated in approximately one-fourth of youth within the first
year of T1D diagnosis in the PDC T1D NeOn Study.8,15
However, among the seven participating pediatric diabetes
centers, the incidence of pump use early in the course of
childhood diabetes varied. Racial/ethnic group, insurance
status, and household income appeared to influence whether
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FIG. 1. Cumulative incidence of pump use (n = 1,012).
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participants were switched from injection to pump therapy,
but HbA1c level did not. Specifically, participants started on
insulin pump therapy were more likely to be non-Hispanic
white, have private health insurance, and have higher annual
household income.
Race, ethnicity, socioeconomic status, and family struc-
ture are complex, interrelated variables that influence each
other. Thus, it was difficult to determine if one variable
was more closely associated with the initiation of insulin
pump therapy than another and to tease out the individual
contribution of each of these variables. However, in the
multivariate analysis, each of these variables remained sta-
tistically significant with the exception of parental education
and family structure. Similarly, the SEARCH for Diabetes in
Youth Study examined predictors of insulin regimen (injec-
tions vs. pump) in youth with T1D and found that use of
FIG. 2. Pump use at 1 year by risk factors. aNumber of participants with missing data: health insurance (n = 22), family
structure (n = 2), family income (n = 338), parent education (n = 184), race/ethnicity (n = 20), diabetic ketoacidosis (DKA) at
diagnosis (n = 30). bKaplan–Meier incidence. cAdjusted for clinical center. d‘‘Other’’ could be living with mother, living with
father, splitting time with mother and father, living with legal guardian who is not parent, living away at school, or other.
eAnalyzed as an ordinal variable. fAge effect varies by center (interaction P< 0.01). For Center F, the incidence of pump use
was 85% (n = 8), 23% (n = 16), 37% (n= 77), and 24% (n= 37) for ages < 2, 2–< 5, 5– < 12, and 12– < 19, respectively (P < 0.001).
For the other six centers the corresponding percentages were 30% (n = 38), 30% (n = 133), 26% (n = 477), and 24% (n= 226) for
ages < 2, 2–< 5, 5–< 12, and 12–< 19, respectively (P = 0.17). gMultivariate analysis using Cox regression. The model contains
all factors with an adjusted value of P < 0.10 to account for potential confounding, but only values of P < 0.01 are considered
statistically significant in this analysis. Factors with blank entries in the multivariate columns were excluded from the model
because P > 0.10. The reference group for each factor is designated with a hazard ratio of 1.0.
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pump therapy was more frequent in older youth, females,
non-Hispanic whites, and families with higher income and
education, even beyond the first year of treatment.16 Com-
pared with the patient population described in the SEARCH
for Diabetes in Youth Study, our patient population was
slightly older upon diagnosis (9.1 vs. 7.8 years) and had a
higher percentage of Hispanic/Latino patients (21% vs.
12%), a lower percentage of non-Hispanic whites (64% vs.
75%), and a lower percentage of patients with private in-
surance (66% vs. 80%).
The results of the PDC T1D NeOn Study also indicated
that the clinical center where participants receive their care
was associated with initiation of insulin pump therapy
within the first year of T1D after adjusting for socioeconomic
status, including health insurance, family structure, annual
household income, parent education, and race/ethnicity. To
further explore this finding, we compared the requirements
and process for pump initiation at the seven PDC centers.
Although all centers required patients to have regular clinic
visits, to check blood glucose four ormore times daily, and to
demonstrate adequate carbohydrate-counting skills, centers
differed in the timing of pump initiation and HbA1c re-
quirement. Some centers were inclined to start patients on
insulin pump therapy early, whereas other centers had
policies to start insulin pump therapy after a 6-month du-
ration of diabetes to allow for mastery of basic diabetes
knowledge and to satisfy insurance requirements. All of the
centers made exceptions for young, toddler-age patients,
who were encouraged to start on insulin pump therapy soon
after diagnosis. Most centers required patients to have an
HbA1c level of less than 9–10%, although one center had no
HbA1c requirement. State-to-state differences in Medicaid
coverage for insulin pumps as well as center differences in
the general approach to and requirements for insulin pump
initiation may have contributed to the variability between
centers in the percentage of participants started on insulin
pump therapy within the first year of diabetes diagnosis in
this study.
A limitation of this study is that detailed information re-
garding parent and participant perceptions of the benefits and
challenges of switching from injection to pump therapy was
not obtained. Families from minority populations or lower
socioeconomic status may have concerns about their ability to
cope with this technology, may be less inclined to inquire
about a pump because of financial concerns, or may have had
their pump request denied by an insurer.17 Similarly, detailed
data are lacking regarding how provider training, experience,
and perceptions may have influenced how individual clini-
cians (even within centers) selected the participants and
families for pump therapy. For example, children from two-
parent households were more likely to be started on insulin
pump therapy than children from single-parent households in
this study. It is possible that providers were more comfortable
prescribing insulin pump therapy for participantswith amore
stable, two-parent family structure.
Additional research is needed in this area to gain a better
understanding of the barriers to insulin pump therapy
for children and adolescents with T1D that may include
patient or family perceptions about insulin pump treat-
ment and provider biases. With a greater understanding of
these barriers and strategies to overcome them, more low-
income and minority families may be able to benefit
from an increase in the availability of advanced diabetes
technologies.
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